Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization

Giulia Girolimetti, Flora Guerra, Luisa Iommarini, Ivana Kurelac, Daniele Vergara, Michele Maffia, Michele Vidone, Laura Benedetta Amato, Giulia Leone, Sabrina Dusi, Valeria Tiranti, Anna Myriam Perrone, Cecilia Bucci, Anna Maria Porcelli, Giuseppe Gasparre

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Development of chemoresistance is a cogent clinical issue in oncology, whereby combination of anticancer drugs is usually preferred also to enhance efficacy. Paclitaxel (PTX), combined with carboplatin, represents the standard first-line chemotherapy for different types of cancers.We here depict a double-edge role of mitochondrial DNA (mtDNA) mutations induced in cancer cells after treatment with platinum. MtDNA mutations were positively selected by PTX, and they determined a decrease in the mitochondrial respiratory function, as well as in proliferative and tumorigenic potential, in terms of migratory and invasive capacity. Moreover, cells bearing mtDNA mutations lacked filamentous tubulin, the main target of PTX, and failed to reorient the Golgi body upon appropriate stimuli.We also show that the bioenergetic and cytoskeletal phenotype were transferred along with mtDNA mutations in transmitochondrial hybrids, and that this also conferred PTX resistance to recipient cells. Overall, our data show that platinum-induced deleterious mtDNA mutations confer resistance to PTX, and confirm what we previously reported in an ovarian cancer patient treated with carboplatin and PTX who developed a quiescent yet resistant tumor mass harboring mtDNA mutations.

Original languageEnglish
Pages (from-to)2961-2974
Number of pages14
JournalHuman Molecular Genetics
Volume26
Issue number15
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Tubulin
Paclitaxel
Platinum
Mitochondrial DNA
Mutation
Carboplatin
Antineoplastic Combined Chemotherapy Protocols
Neoplasms
Ovarian Neoplasms
Energy Metabolism
Phenotype
Drug Therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Girolimetti, G., Guerra, F., Iommarini, L., Kurelac, I., Vergara, D., Maffia, M., ... Gasparre, G. (2017). Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization. Human Molecular Genetics, 26(15), 2961-2974. https://doi.org/10.1093/hmg/ddx186

Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization. / Girolimetti, Giulia; Guerra, Flora; Iommarini, Luisa; Kurelac, Ivana; Vergara, Daniele; Maffia, Michele; Vidone, Michele; Amato, Laura Benedetta; Leone, Giulia; Dusi, Sabrina; Tiranti, Valeria; Perrone, Anna Myriam; Bucci, Cecilia; Porcelli, Anna Maria; Gasparre, Giuseppe.

In: Human Molecular Genetics, Vol. 26, No. 15, 01.08.2017, p. 2961-2974.

Research output: Contribution to journalArticle

Girolimetti, G, Guerra, F, Iommarini, L, Kurelac, I, Vergara, D, Maffia, M, Vidone, M, Amato, LB, Leone, G, Dusi, S, Tiranti, V, Perrone, AM, Bucci, C, Porcelli, AM & Gasparre, G 2017, 'Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization', Human Molecular Genetics, vol. 26, no. 15, pp. 2961-2974. https://doi.org/10.1093/hmg/ddx186
Girolimetti, Giulia ; Guerra, Flora ; Iommarini, Luisa ; Kurelac, Ivana ; Vergara, Daniele ; Maffia, Michele ; Vidone, Michele ; Amato, Laura Benedetta ; Leone, Giulia ; Dusi, Sabrina ; Tiranti, Valeria ; Perrone, Anna Myriam ; Bucci, Cecilia ; Porcelli, Anna Maria ; Gasparre, Giuseppe. / Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization. In: Human Molecular Genetics. 2017 ; Vol. 26, No. 15. pp. 2961-2974.
@article{61118e6f2ca94a45af65817bb1e3830d,
title = "Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization",
abstract = "Development of chemoresistance is a cogent clinical issue in oncology, whereby combination of anticancer drugs is usually preferred also to enhance efficacy. Paclitaxel (PTX), combined with carboplatin, represents the standard first-line chemotherapy for different types of cancers.We here depict a double-edge role of mitochondrial DNA (mtDNA) mutations induced in cancer cells after treatment with platinum. MtDNA mutations were positively selected by PTX, and they determined a decrease in the mitochondrial respiratory function, as well as in proliferative and tumorigenic potential, in terms of migratory and invasive capacity. Moreover, cells bearing mtDNA mutations lacked filamentous tubulin, the main target of PTX, and failed to reorient the Golgi body upon appropriate stimuli.We also show that the bioenergetic and cytoskeletal phenotype were transferred along with mtDNA mutations in transmitochondrial hybrids, and that this also conferred PTX resistance to recipient cells. Overall, our data show that platinum-induced deleterious mtDNA mutations confer resistance to PTX, and confirm what we previously reported in an ovarian cancer patient treated with carboplatin and PTX who developed a quiescent yet resistant tumor mass harboring mtDNA mutations.",
author = "Giulia Girolimetti and Flora Guerra and Luisa Iommarini and Ivana Kurelac and Daniele Vergara and Michele Maffia and Michele Vidone and Amato, {Laura Benedetta} and Giulia Leone and Sabrina Dusi and Valeria Tiranti and Perrone, {Anna Myriam} and Cecilia Bucci and Porcelli, {Anna Maria} and Giuseppe Gasparre",
year = "2017",
month = "8",
day = "1",
doi = "10.1093/hmg/ddx186",
language = "English",
volume = "26",
pages = "2961--2974",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization

AU - Girolimetti, Giulia

AU - Guerra, Flora

AU - Iommarini, Luisa

AU - Kurelac, Ivana

AU - Vergara, Daniele

AU - Maffia, Michele

AU - Vidone, Michele

AU - Amato, Laura Benedetta

AU - Leone, Giulia

AU - Dusi, Sabrina

AU - Tiranti, Valeria

AU - Perrone, Anna Myriam

AU - Bucci, Cecilia

AU - Porcelli, Anna Maria

AU - Gasparre, Giuseppe

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Development of chemoresistance is a cogent clinical issue in oncology, whereby combination of anticancer drugs is usually preferred also to enhance efficacy. Paclitaxel (PTX), combined with carboplatin, represents the standard first-line chemotherapy for different types of cancers.We here depict a double-edge role of mitochondrial DNA (mtDNA) mutations induced in cancer cells after treatment with platinum. MtDNA mutations were positively selected by PTX, and they determined a decrease in the mitochondrial respiratory function, as well as in proliferative and tumorigenic potential, in terms of migratory and invasive capacity. Moreover, cells bearing mtDNA mutations lacked filamentous tubulin, the main target of PTX, and failed to reorient the Golgi body upon appropriate stimuli.We also show that the bioenergetic and cytoskeletal phenotype were transferred along with mtDNA mutations in transmitochondrial hybrids, and that this also conferred PTX resistance to recipient cells. Overall, our data show that platinum-induced deleterious mtDNA mutations confer resistance to PTX, and confirm what we previously reported in an ovarian cancer patient treated with carboplatin and PTX who developed a quiescent yet resistant tumor mass harboring mtDNA mutations.

AB - Development of chemoresistance is a cogent clinical issue in oncology, whereby combination of anticancer drugs is usually preferred also to enhance efficacy. Paclitaxel (PTX), combined with carboplatin, represents the standard first-line chemotherapy for different types of cancers.We here depict a double-edge role of mitochondrial DNA (mtDNA) mutations induced in cancer cells after treatment with platinum. MtDNA mutations were positively selected by PTX, and they determined a decrease in the mitochondrial respiratory function, as well as in proliferative and tumorigenic potential, in terms of migratory and invasive capacity. Moreover, cells bearing mtDNA mutations lacked filamentous tubulin, the main target of PTX, and failed to reorient the Golgi body upon appropriate stimuli.We also show that the bioenergetic and cytoskeletal phenotype were transferred along with mtDNA mutations in transmitochondrial hybrids, and that this also conferred PTX resistance to recipient cells. Overall, our data show that platinum-induced deleterious mtDNA mutations confer resistance to PTX, and confirm what we previously reported in an ovarian cancer patient treated with carboplatin and PTX who developed a quiescent yet resistant tumor mass harboring mtDNA mutations.

UR - http://www.scopus.com/inward/record.url?scp=85026326314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026326314&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddx186

DO - 10.1093/hmg/ddx186

M3 - Article

VL - 26

SP - 2961

EP - 2974

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 15

ER -